Nereus

(Tradipitant)

Phase 3Small molecule

VVanda Pharmaceuticals

Nereus is one of 101 small molecule programs targeting Gastroparesis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

100

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

GastroparesisRecruiting

Functional DyspepsiaEnrolling by invitation

Nausea and VomitingNot yet recruiting

Motion SicknessCompleted

COVID-19Enrolling by invitation

GastroparesisPhase 3

Recruiting

Functional DyspepsiaPhase 2

Enrolling by invitation

Nausea and VomitingPhase 3

Not yet recruiting

Motion SicknessPhase 3

Completed

COVID-19Phase 3

Enrolling by invitation

Competition

Competitive Landscape

317 competitors in COVID-19

#DrugCompanyPhaseTrials

Nereus

VVanda Pharmaceuticals

Phase 3

1 2

Stivarga

Bayer

Preclinical

1 3

Aimovig

Amgen

Preclinical

1 4

Aldactone

Pfizer

Preclinical

1 5

Nexavar

Bayer

Preclinical

1 6

Calciferol

Activella

Angiomax

BBaxter Healthcare Corporation

Preclinical

2 9

Tricor

JJagotec

Preclinical

1 10

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Not yet recruiting

Nausea and Vomiting

NCT07446439

Clinical

Trials by Indication[1]

Motion Sickness4 trials

Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness

Completed·VVanda Pharmaceuticals·Phase 3·NCT05903924·316 enrolled

Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness

Completed·VVanda Pharmaceuticals·Phase 3·NCT04327661·366 enrolled

Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness

Completed·VVanda Pharmaceuticals·Phase 2·NCT03772340·126 enrolled

Show 1 more trial

Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness

Active, not recruiting·VVanda Pharmaceuticals·Phase 3·NCT06138613·705 enrolled

Atopic Dermatitis3 trials

Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2)

Terminated·VVanda Pharmaceuticals·Phase 3·NCT04140695·87 enrolled

Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis

Completed·VVanda Pharmaceuticals·Phase 2·NCT02651714·168 enrolled

Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE)

Completed·VVanda Pharmaceuticals·Phase 3·NCT03568331·375 enrolled

Gastroparesis3 trials

Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis

Completed·VVanda Pharmaceuticals·Phase 3·NCT04028492·992 enrolled

Single-Patient Expanded Access Protocol for Tradipitant In A Single Patient With Gastroparesis

Available·VVanda Pharmaceuticals··NCT04474990

Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis

Recruiting·VVanda Pharmaceuticals·Phase 3·NCT06836557·100 enrolled

Nausea and vomiting2 trials

A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use

Completed·VVanda Pharmaceuticals·Phase 2·NCT06804603·124 enrolled

A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use

Not yet recruiting·VVanda Pharmaceuticals·Phase 3·NCT07446439·280 enrolled

Midazolam1 trial

Study to Assess the Effect of Multiple Doses of Tradipitant on CYP3A4 Using Midazolam as a Substrate in Healthy Subjects

Completed·VVanda Pharmaceuticals·Phase 1·NCT02621385·24 enrolled

3 more indications

Gastric Emptying1 trial

Effects of Tradipitant on Satiation, Gastric Volume, Gastric Accommodation, and Gastric Emptying in Healthy Volunteers

Completed·VVanda Pharmaceuticals·Phase 1/2·NCT04849559·27 enrolled

COVID-191 trial

ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection

Enrolling by invitation·VVanda Pharmaceuticals·Phase 3·NCT04326426·300 enrolled

Functional Dyspepsia1 trial

Pharmacodynamics, Pharmacogenetics, Clinical Efficacy and Safety of Tradipitant for Functional Dyspepsia

Enrolling by invitation·XXiao Jing (Iris) Wang·Phase 2·NCT05653310·60 enrolled

Regulatory

FDA Approval Timeline[4]

Dec 30, 2025

NEREUS

NDA NDA220152

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for Tradipitant. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tradipitant compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tradipitant. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA220152). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Nereus. U.S. Food & Drug Administration.
[6]
SEC EDGAR — Vanda Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: VVanda Pharmaceuticals

Patent Landscape[5]

Patent Cliff

Mar 4, 2036

Earliest patent expiration — generic entry possible after this date

Patent #Expires

11324735Mar 4, 2036

10821099Mar 4, 2036

10772880Mar 4, 2036

12318375Aug 9, 2036

Nereus

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Motion Sickness4 trials

Atopic Dermatitis3 trials

Gastroparesis3 trials

Nausea and vomiting2 trials

Midazolam1 trial

Gastric Emptying1 trial

COVID-191 trial

Functional Dyspepsia1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Related News